Recent advances in uncovering the mechanisms contributing to BIRD-2-induced cell death in B-cell cancer cells

Martijn Kerkhofs¹, Tamara Vervloessem¹, Mart Bittremieux¹ and Geert Bultynck¹

A common observation in hematological cancer cells, including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), is the upregulation of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein, the founding member of the Bcl-2-protein family. Bcl-2 overexpression enables cancer cell survival despite pro-apoptotic challenges related to oncogenic stress such as genomic aberrations. Bcl-2 protects cells against apoptosis through means other than its canonical anti-apoptotic function. Indeed, Bcl-2 can also protect cells against apoptosis through means other than its canonical anti-apoptotic function. Recently, venetoclax has been approved by the Food and Drug Administration (FDA) for the treatment of patients with relapsed CLL.

However, it has become clear that Bcl-2 overexpression can also protect cells against apoptosis through means other than its canonical anti-apoptotic function. Indeed, work from several labs indicated that Bcl-2 is present at the endoplasmic reticulum (ER) Ca²⁺ stores, where it diminishes Ca²⁺ efflux from the ER. Although different mechanisms have been proposed, it is clear that Bcl-2, via its BH4 domain, can directly bind IP₃ receptors (IP₃Rs)—intracellular Ca²⁺-release channels—and limit their Ca²⁺-flux properties, thereby preventing cell death driven by Ca²⁺ overload.

Bcl-2-IP₃R disrupter-2 (BIRD-2), a cell-permeable peptide tool that targets Bcl-2’s BH4 domain has been developed by fusing the TAT sequence to a stretch of 20 amino acids representing the Bcl-2-binding site present in the central, modulatory region of the IP₃R. This peptide is able to disrupt the interaction between the IP₃R and Bcl-2, BIRD-2 provoked spontaneous IP₃R-mediated Ca²⁺ signaling and cell death in several Bcl-2-dependent cancer cell models, including CLL, multiple myeloma and follicular lymphoma, small cell lung cancer, and DLBCL.

Interestingly, in DLBCL at least, we discovered a negative correlation between the sensitivity towards venetoclax and BIRD-2. Therefore, we may speculate that a cancer cell needs to choose to deploy Bcl-2 for its canonical role at the mitochondria, preventing Bax/Bak activity, or an alternative function at the ER, inhibiting IP₃R activity. The former depends on Bcl-2’s hydrophobic cleft, whereas its BH4 domain is involved in the latter.

Recent work from our lab has shed more light on the mechanism of action of BIRD-2. A paper by Bittremieux et al. highlights the importance of intra- and extracellular Ca²⁺ for BIRD-2 to work. We initially hypothesized that store-operated Ca²⁺ entry (SOCE) is an important process in BIRD-2-induced cell death. After all, BIRD-2 promotes Ca²⁺ release from the ER, which would be refilled upon depletion by SOCE. During Ca²⁺ depletion, the luminal ER Ca²⁺ sensor STIM1 interacts with ORAI, a plasma membrane resident Ca²⁺-influx channel. This interaction results in the activation of ORAI and Ca²⁺ influx, refilling the ER. However, Bittremieux et al. showed that SOCE is not necessary for BIRD-2-induced cell death. They did this by using several...
well-characterized pharmacological tools, including DPB162-AE, YM-58483, and GSK-7975A. All compounds were shown to inhibit SOCE, but, interestingly, only DPB162-AE could reduce BIRD-2-induced cell death. This discrepancy was explained by DPB162-AE’s effect on ER Ca\(^{2+}\) store filling, since treatment with thapsigargin and cyclopiazonic acid, two other molecules reducing the ER Ca\(^{2+}\) store but without effect on SOCE, too, could protect against BIRD-2-induced cell death. These experiments confirm and highlight the importance of ER Ca\(^{2+}\) in BIRD-2’s working mechanism. The case against the involvement of SOCE in BIRD-2-mediated cell death was strengthened by a knock-down of STIM1. Cell death experiments comparing the knock-down and the wild-type showed no significant difference between the two conditions\(^{11}\). Caution with the interpretation of these results is warranted, since both the pharmacological and genetic approaches may not have completely annihilated SOCE and thus remnant SOCE could have been sufficient for BIRD-2-induced cell death.

Although SOCE was excluded as a major factor in the cell death mechanism underlying BIRD-2, there was an indication that extracellular Ca\(^{2+}\) is important for proper cell death induction by BIRD-2\(^{11}\). Experiments performed with ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) in the extracellular medium showed that the intracellular Ca\(^{2+}\) signal, elicited by BIRD-2, is not present when Ca\(^{2+}\) is chelated in the extracellular environment. This implies that extracellular Ca\(^{2+}\) is involved in killing the cells with BIRD-2. However, the molecular identity of the pathway mediating Ca\(^{2+}\) influx from the extracellular medium remains elusive and requires further investigation\(^{11}\).

Independently from this, our lab has also identified other factors that contribute to the sensitivity of DLBCL cancer cells towards BIRD-2 exposure (Fig. 1). A first factor is the expression of particular IP\(_3\)R isoforms\(^{12}\). We found that cells displaying high IP\(_3\)R2 subtype expression are most sensitive towards BIRD-2. It is hypothesized that these cells are more sensitive to disinhibition of the IP3R

---

**Fig. 1 Antagonizing B-cell lymphoma 2 (Bcl-2) to induce cell death in B-cell cancer cells.** Two functional domains, the hydrophobic cleft and the BH4 domain, are important for Bcl-2’s anti-apoptotic function. The hydrophobic cleft of Bcl-2 prevents apoptosis by scaffolding and neutralizing several pro-apoptotic Bcl-2 family members, including Bax/Bak and BH3-only proteins such as Bim, at the mitochondrial outer membranes. The hydrophobic cleft of Bcl-2 can be targeted by so-called BH3 mimetics, including the recently FDA-approved small molecule venetoclax/ABT-199, provoking cell death in Bcl-2-dependent cancer cells. The BH4 domain suppresses apoptosis by binding and inhibiting the IP3R, intracellular Ca\(^{2+}\)-release channels present in the endoplasmic reticulum (ER). A decoy peptide, the Bcl-2 IP\(_3\)R disruptor-2 (BIRD-2), can target Bcl-2’s BH4 domain, thereby disrupting Bcl-2/IP3R complexes and provoking Ca\(^{2+}\)-driven apoptosis in Bcl-2-dependent cancer cells. The IP3R isoform subtype (IP3R2), constitutive IP3 signaling and extracellular Ca\(^{2+}\) are critical factors that contribute to the sensitivity of Bcl-2-dependent cancer cells towards BIRD-2 (indicated in green), while store-operated Ca\(^{2+}\) entry likely may not be involved (indicated in red).
due to Bcl-2 removal from the channel, because the IP₃R₂ has the highest affinity for its ligand IP₃. A second factor that contributes to BIRD-2 sensitivity is constitutive IP₃ signaling. B-cell cancers are often characterized by tonic or chronic B-cell receptor (BCR) activity. Importantly, phospholipase γ₂, an enzyme producing IP₃ and diacyl glycerol from phosphatidylinositol 4,5-bisphosphate (PIP₂) present in the cell membrane, acts downstream of this hyperactive BCR, thus providing a constant source of IP₃ that helps to promote cell survival and growth. Treatment of DLBCL and primary CLL cells with a chemical inhibitor of phospholipase C suppressed the ability of BIRD-2 to provoke cell death. At least in DLBCL cell lines, these pharmacological experiments were independently validated by the overexpression of an IP₃ sponge that buffers free IP₃, thereby dampening BIRD-2-induced cell death. So, although these tumor cells use constitutive IP₃ signaling as a pro-survival mechanism, this signaling system can be converted into a pro-death signal by BIRD-2. Now, further research is needed to examine whether BIRD-2 can also kill other primary cancer cells besides the ones derived from CLL patients and whether BIRD-2 sensitivity is dependent on IP₃R₂ expression and IP₃ signaling in these primary cells.

Finally, BIRD-2 can be used to eradicate cancer cells, even when it is not directly killing the cells itself. In ovarian cancer cells, Bcl-2 has been implicated in cisplatin resistance. Recent work by Xie et al. shows that BIRD-2 can overcome cisplatin resistance, thereby re-sensitizing ovarian cancer cells towards cisplatin. At the mechanistic level, BIRD-2 augmented cisplatin-induced Ca²⁺ release and cell death without causing cell death by itself in these cells. These findings would advocate for opportunities to apply BIRD-2 as an adjuvant for other antitumor treatments that impinge on Ca²⁺ signaling.

Acknowledgements

Research in the authors’ laboratory related to this topic has been supported by the Research Foundation—Flanders (FWO) (G.0.C.91.14 N, G.0.A34.16 N), the Research Council—KU Leuven (OT14/101). M.K. and M.B. are holders of a Ph.D. fellowship from the FWO. We also thank all co-authors of the original research papers for their important contributions to the work. We also wish to apologize to all authors whose papers could not be cited due to space limitations.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 December 2018 Accepted: 12 December 2018 Published online: 17 January 2019

References

1. Montero, J. et al. Why do Bcl-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 25, 56–64 (2018).
2. Green, D. R. A BH3 Mimetic for Killing Cancer Cells. Cell 165, 1560 (2016).
3. Akl, H. et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer mitochondria versus endoplasmic reticulum. Biochim. Biophys. Acta Mol. Cell Res. 1843, 2240–2252 (2014).
4. Vervliet, T. et al. Bcl-2 proteins and calcium signaling: complexity beneath the surface. Oncogene 35, 5079–5092 (2016).
5. Rong, Y. P. et al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP₃ receptor. Proc. Natl. Acad. Sci. USA 106, 14397–14402 (2009).
6. Distelhorst, C. W. Creating a New Cancer Therapeutic Agent by Targeting Bcl-2/IP3R Interaction. Cold Spring Harb. Perspect. Biol. (2019) (in press).
7. Distelhorst, C. W. Targeting Bcl-2/IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones. Biochim. Biophys. Acta Mol. Cell Res. 11, 1795–1804 (2018).
8. Zhong, F. et al. Induction of Ca(2)⁺-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2/IP3 receptor interaction. Blood 117, 2924–2934 (2011).
9. Lavk, A. R. et al. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. Oncotarget 6, 27388–27402 (2015).
10. Vervloessem, T. et al. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax. Oncotarget 8, 111656–111671 (2017).
11. Bittremieux, M. et al. Extracellular and ER-stored Ca²⁺ contribute to BIRD-2-induced cell death in diffuse large B-cell lymphoma cells. Cell Death Discov. 4, 101 (2018).
12. Akl, H. et al. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2. Cell Death Dis. 4, e632 (2013).
13. Bittremieux, M. et al. Constitutive IP₃ signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP₃ receptor disruptor BIRD-2. Cell Death Differ. https://doi.org/10.1038/s41418-018-0142-3 (2018).
14. Fowler, N. et al. Targeting B-cell receptor signaling: changing the paradigm. Hematol. Am. Soc. Hematol. Educ. Program 2013, 553–560 (2013).
15. Xie, Q. et al. TAT-fused IP₃R-derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca²⁺ release. Int. J. Mol. Med. 41, 809–817 (2018).